Hematologic Diseases: Clinical Trials

1,136 trials for Hematologic Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1136 terminated. 1136 Phase 2, 328 Phase 1, 30 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 21136Terminated 1136
Phase 1328Terminated 328
Phase 330Terminated 30

Follow Hematologic Diseases: new trials by email Literature Review of Hematologic Diseases trials Research Report on Hematologic Diseases

Trials (filtered) newest first · largest first

All 1,136 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Open-Label Extension Study to Pioneer Study 6058-SCD-101
Pociredir - Sickle Cell Disease
Phase 2TerminatedFulcrum Therapeutics12026-03-302026-10-28
Multiple CAR-T Cell Therapy Targeting AML
CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells - Acute Myeloid Leukemia
Phase 1 / Phase 2TerminatedShenzhen Geno-Immune Medical Institute102025-08-012026-11-02
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
4SCAR19 and 4SCAR22, 4SCAR19 and 4SCAR38, 4SCAR19 and 4SCAR20 - B-cell Malignancies
Phase 1 / Phase 2TerminatedShenzhen Geno-Immune Medical Institute1002025-08-012026-10-30
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
S227928, Venetoclax - Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML
Phase 1 / Phase 2TerminatedServier Bio-Innovation LLC132025-02-252026-03-30
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
SOC + BSB-1001 Dose Escalation Cohort, SOC+BSB-1001 Expansion Dose - AML, Adult Recurrent, ALL, Recurrent, Adult
Phase 1 / Phase 2TerminatedBlueSphere Bio, Inc22025-02-042026-09-10
BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B
BE-101 - Hemophilia B, Hemophilia B, Moderately Severe or Severe
Phase 1 / Phase 2TerminatedBe Biopharma52024-12-042026-06-15
Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML
Luveltamab tazevibulin - Acute Myeloid Leukemia (AML)
Phase 1 / Phase 2TerminatedSutro Biopharma, Inc.12024-12-042026-10-13
Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization
Anti-(integrin beta-3) human monoclonal antibody - Fetal and Neonatal Alloimmune Thrombocytopenia
Phase 2TerminatedRallybio12024-11-212026-03-06
Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia
Reduced dose of cyclophosphamide combined with standard immunosuppressive therapy - Severe Aplastic Anemia, Cyclophosphamide Reduced-dose
Phase 2TerminatedInstitute of Hematology & Blood Diseases Hospital, China142024-11-012026-11-04
RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis
RVU120, Ruxolitinib - Myelofibrosis
Phase 2TerminatedRyvu Therapeutics SA362024-09-192026-09-16
Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]
NP137, Azacitidine Injection, Venetoclax - Acute Myeloid Leukemia Refractory
Phase 1 / Phase 2TerminatedCentre Leon Berard12024-09-112025-02-20
A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies
SAR443579, venetoclax, azacitidine - Acute Myeloid Leukemia
Phase 1 / Phase 2TerminatedSanofi72024-08-132026-10-19
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
INZ-701 - Gene Mutations, Pseudoxanthoma Elasticum
Phase 2TerminatedInozyme Pharma222024-06-192026-10-19
A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)
TQ05105 tablets, TQB3909 tablets - Myelofibrosis
Phase 1 / Phase 2TerminatedChia Tai Tianqing Pharmaceutical Group Co., Ltd.212024-05-132026-01-05
Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML
RVU120 - Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome
Phase 2TerminatedRyvu Therapeutics SA622024-01-232026-09-16
Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant
VCAR33 - Leukemia, Myeloid, Acute
Phase 1 / Phase 2TerminatedVor Biopharma382023-12-112025-07-29
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
Forimtamig, Carfilzomib, Daratumumab - Relapsed or Refractory Multiple Myeloma
Phase 1 / Phase 2TerminatedHoffmann-La Roche212023-12-082026-09-29
Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes
KPT-8602, Inqovi, Bone marrow aspirate - Myelodysplastic Syndromes
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)32023-11-142025-12-02
Siplizumab for Sickle Cell Disease Transplant
Siplizumab, Exchange Transfusion, Total Body Irradiation - Anemia, Sickle Cell
Phase 1 / Phase 2TerminatedColumbia University12023-09-282026-06-10
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
VLX-1005, Placebo - Thrombocytopenia, Immune, Heparin Induced Thrombocytopenia
Phase 2TerminatedVeralox Therapeutics242023-09-262025-11-25

Showing 20 of 1136. Sign in to see all of them.

Narrower conditions

Multiple Myeloma (247)  ·  Leukemia, Myeloid, Acute (239)  ·  Leukemia (184)  ·  Myelodysplastic Syndromes (182)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (156)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (131)  ·  Lymphoma (92)  ·  Lymphoma, Non-Hodgkin (89)  ·  Recurrence (78)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (72)  ·  Hematologic Neoplasms (59)  ·  Lymphoma, Large B-Cell, Diffuse (57)  ·  Lymphoma, Follicular (55)  ·  Anemia (54)  ·  Lymphoma, Mantle-Cell (50)

Broader conditions

Hemic and Lymphatic Diseases (1136)  ·  Neoplasms (820)  ·  Neoplasms by Histologic Type (806)  ·  Immune System Diseases (592)  ·  Immunoproliferative Disorders (547)  ·  Lymphoproliferative Disorders (534)  ·  Leukemia (389)  ·  Pathological Conditions, Signs and Symptoms (386)  ·  Pathologic Processes (379)  ·  Lymphatic Diseases (349)  ·  Hemorrhagic Disorders (336)  ·  Disease Attributes (332)  ·  Bone Marrow Diseases (324)  ·  Leukemia, Myeloid (311)

Interventions

Cyclophosphamide (104)  ·  Dexamethasone (90)  ·  Cytarabine (70)  ·  Rituximab (69)  ·  fludarabine (68)  ·  fludarabine phosphate (66)  ·  Bortezomib (56)  ·  Azacitidine (53)  ·  Lenalidomide (51)  ·  Calcium Dobesilate (45)  ·  Busulfan (43)  ·  Methotrexate (40)  ·  Whole-Body Irradiation (40)  ·  Filgrastim (39)  ·  Melphalan (39)

Sponsors

M.D. Anderson Cancer Center (83)  ·  National Cancer Institute (NCI) (41)  ·  Masonic Cancer Center, University of Minnesota (27)  ·  Novartis Pharmaceuticals (27)  ·  Fred Hutchinson Cancer Center (22)  ·  Mayo Clinic (16)  ·  Gilead Sciences (15)  ·  Weill Medical College of Cornell University (15)  ·  Incyte Corporation (13)  ·  OHSU Knight Cancer Institute (13)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (13)  ·  Washington University School of Medicine (13)  ·  St. Jude Children's Research Hospital (12)  ·  Baylor College of Medicine (11)  ·  Emory University (10)

Countries

United States (880)  ·  France (100)  ·  Italy (92)  ·  United Kingdom (83)  ·  Germany (82)  ·  Spain (79)  ·  Canada (71)  ·  Australia (46)  ·  Belgium (35)  ·  Netherlands (31)  ·  South Korea (31)  ·  Poland (26)  ·  Denmark (24)  ·  China (23)  ·  Austria (21)

Top investigators

Courtney DiNardo, MD (5)  ·  Jorge Cortes, MD (5)  ·  Guillermo Garcia-Manero, MD (4)

Results publications

PMID 39903535, PMID 32031570, PMID 32171076, PMID 29515037, PMID 35622074, PMID 23053510, PMID 26472751, PMID 28835440, PMID 30885996, PMID 31527168, PMID 34398557, PMID 35857660, PMID 36791280, PMID 41671463, PMID 42749863, PMID 10499616, PMID 11071652, PMID 11222401, PMID 12011123, PMID 12637486, PMID 12791647, PMID 1348362, PMID 14550808, PMID 14551141, PMID 15381930, PMID 15486072, PMID 16304375, PMID 16403905, PMID 16609072, PMID 16622268, PMID 16651647, PMID 1707752, PMID 17579184, PMID 17602062, PMID 17611569, PMID 18463354, PMID 18946659, PMID 19118065, PMID 19139736, PMID 19179301, PMID 19826119, PMID 20059562, PMID 20067838, PMID 20307284, PMID 21145590, PMID 21275961, PMID 21381892, PMID 21403127, PMID 21420732, PMID 21527519

NIH funding

2018 (18), P30CA015704 (14), 2016 (10), 2019 (10), 2017 (9), P30CA015083 (9), 2014 (8), P30CA016672 (8), 2008 (7), 2023 (7), 2009 (6), U10CA021115 (6), 2015 (4), P01CA018029 (4), P30CA006973 (4)